Brief: Theranexus H1 Operating Loss Widens to 2.9 Million Euros
Sept 27 (Reuters) - THERANEXUS SA ALTHX.PA :
* CASH AVAILABLE AT JUNE 30: 14.9 MILLION EUR
* H1 NET LOSS EUR 2.1 MILLION VERSUS LOSS EUR 0.7 MILLION
YEAR AGO
* H1 OPERATING LOSS EUR 2.9 MILLION VERSUS LOSS EUR 0.9
MILLION
YEAR AGO
* GENERATED NO REVENUE IN H1
Source text: https://bit.ly/2N76ARZ
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease